Certara Inc. (CERT)
NASDAQ: CERT
· Real-Time Price · USD
11.56
0.02 (0.13%)
At close: Sep 26, 2025, 11:05 AM
0.13% (1D)
| Bid | 11.55 |
| Market Cap | 1.86B |
| Revenue (ttm) | 405.75M |
| Net Income (ttm) | 7.98M |
| EPS (ttm) | 0.05 |
| PE Ratio (ttm) | 231.3 |
| Forward PE | 20.84 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 11.58 |
| Volume | 178,638 |
| Avg. Volume (20D) | 1,625,714 |
| Open | 11.57 |
| Previous Close | 11.54 |
| Day's Range | 11.53 - 11.73 |
| 52-Week Range | 8.63 - 15.69 |
| Beta | 1.43 |
| Ex-Dividend Date | n/a |
About CERT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CERT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CERT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsCertara Inc. is scheduled to release its earnings on
Nov 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-11.03%
Certara shares are trading lower following Q1 repo...
Unlock content with
Pro Subscription
5 months ago
+11.54%
Certara shares are trading higher after the company issued a year-over-year increase in its Q1 revenue guidance and announced a $100 million share repurchase program. Additionally, the company announced it launched a non-animal navigator solution to help drug developers reduce reliance on animal testing.
2 months ago · seekingalpha.com
Certara: Ideally Positioned To Benefit From IT Innovation In Life SciencesCertara is a leader in Model-Informed Drug Development (MIDD), offering essential software and services that reduce drug development costs and time. The company's diversified software portfolio and gr...